NCT05923970 Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
| NCT ID | NCT05923970 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alberta |
| Condition | Vaccination Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-11-09 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-11-09 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The current recommendation for a full course of measles-mumps-rubella-(varicella) vaccine (MMR(V)) is two doses. The problem is, many individuals within the vaccinated cohort show antibody levels that are below the level considered to be protective, even after two doses of vaccine. Because of these waning antibody levels, it is currently unknown whether highly vaccinated populations are protected from infection against measles, mumps, rubella, or varicella should they be exposed to any of these viruses. The uncertainty of a woman's immune status is partly due to the type of testing that is used to indicate protection. While immunity to viral infection requires both a humoral and a cell mediated immune (CMI) response, only humoral (antibody) responses are measured routinely in the laboratory. This study will examine CMI responses and the role of a third dose of vaccine for previously vaccinated women whose antibody levels are below the cut off. This study will not administer vaccine, but rather will include women who have received a third dose of vaccination through routine health care follow up in the study cohort.
Eligibility Criteria
Inclusion Criteria: * Women who are pregnant and have undergone routine prenatal screening for rubella antibodies. Exclusion Criteria: * Women younger than 18 years of age
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05923970 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Vaccination Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05923970 currently recruiting?
Yes, NCT05923970 is actively recruiting participants. Contact the research team at carmen.charlton@albertahealthservices.ca for enrollment information.
Where is the NCT05923970 trial being conducted?
This trial is being conducted at Edmonton, Canada.
Who is sponsoring the NCT05923970 clinical trial?
NCT05923970 is sponsored by University of Alberta. The trial plans to enroll 200 participants.